Toronto, Canada – CardioComm Solutions, Inc. (TSX-V:EKG) (“CardioComm Solutions” or the “Company”), a global provider of consumer heart monitoring and medical electrocardiogram (“ECG”) device and management software solutions, is pleased to announce their participation in this year’s Cardiovascular Health issue for the American Heart Awareness Campaign that will be released March 25, 2016.
In collaboration with the American College of Cardiology and American Heart Association, CardioComm Solutions’ HeartCheck™ ECG PEN will be promoted in the USA Today based Cardiovascular Health publication. The Campaign itself will serve as a call to action for the millions of Americans living with heart disease to become aware of credible technologies that are available to help them take control of their health. The publication will introduce available innovations in heart monitoring and will carry advertising for the HeartCheck™ ECG PEN.
The HeartCheck™ promotion will have an expected reach of at least 1.3 million readers in the following US cities: New York, Chicago, Washington D.C., San Francisco, Pittsburgh, Cleveland, Boston and Seattle.
The Cardiovascular Health publication itself will also be distributed to 19,000 attendees and cardiovascular medical professionals at the 65th American College of Cardiology’s Expo (ACC.16) in Chicago to be held April 4th to 6th and will be featured on the Future of Personal Health website (http://www.futureofpersonalhealth.com/). A separate press release announcing CardioComm Solutions’ sponsorship of the Heart Awareness Campaign will be distributed by the campaign organizers through over 500 of the largest media outlets. CardioComm Solutions has also been quoted in a short editorial in the publication regarding personal medical technologies used in cardiac care.
The HeartCheck™ ECG PEN and free GEMS™ Home software hold FDA clearances as ECG monitoring solutions that can be sold directly to consumers with or without a physician’s prescription therefore making it possible for anyone to take an active role in maintaining their heart health at any time. With respect to physician preference, in addition to the handheld use of the HeartCheck™ device to record an ECG (Lead I), the device can also be held in the right hand and pressed against the left side of the chest, or ribs, to record a Lead II ECG which is better when screening for arrhythmias. Physicians can also recommend the HeartCheck™ devices to their patients and can bill for reviewing the GEMS™ Home generated ECG reports under available third party payer ECG reimbursement codes.
Using the HeartCheck™ device, a 30 second ECG recording can be taken that can confirm the presence or absence of an arrhythmia. Any recorded ECG can be uploaded to CardioComm Solutions’ HIPAA compliant SMART Monitoring ECG reading service to provide an ECG interpretation and report back to HeartCheck™ ECG PEN users. A market advantage of the HeartCheck™ ECG PEN is that it is a small and fully contained ECG device that can independently record, save, replay and transfer recorded ECGs to a computer. The free GEMS™ Home software and SMART Monitoring technologies are based on established ECG software technologies that are currently licensed by the Company to hospitals and clinics across the USA.
To learn more about the CardioComm Solutions’ HeartCheck™ products and to keep informed on new devices that the Company plans to bring to the consumer ECG market please see the Company’s websites www.theheartcheck.com andwww.cardiocommsolutions.com or contact the Company at firstname.lastname@example.org.